We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New US legislation Aims to Phase Out Invasive Research on Great Apes

By LabMedica International staff writers
Posted on 14 Aug 2012
US Senate Environment and Public Works Committee recently approved the Great Ape Protection and Cost Savings Act (S. More...
810) and urged its passage in the full US Senate. Since Chimpanzees are the only great apes currently used in invasive research in the US, the new legislation will phase out such research on chimpanzees, end breeding of chimpanzees for invasive research purposes, and retire the 500 government-owned chimpanzees to sanctuary, saving approximately USD 25 million per year.

However, according to the act, the term Great Ape refers to Chimpanzees (Pan troglodytes), Bonobos (P. paniscus), Gorillas (Gorilla gorilla or G. beringei), Orangutans (Pongo pygmaeus or Pongo abelii), and Gibbons (Hylobatidae).

The bill was introduced by US Senators Maria Cantwell, Democrat-Washington, Susan Collins, Republican-Maine, and Bernard Sanders, Independent-Vermont.

S. 810 passed the committee by voice vote with the inclusion of an amendment that allows for invasive research on great apes in the event that a new, emerging, or reemerging disease requires their use. Approval for research will involve a transparent process that closely tracks the recommendations of a recent Institute of Medicine of the [US] National Academies (IOM; Washington DC, USA) report that concluded chimpanzees are largely unnecessary for current biomedical research.

The Great Ape Protection and Cost Savings Act was introduced in April 2011. A recent report by the Institute of Medicine and National Research Council could not identify any area of current biomedical research for which chimpanzee use is necessary. Moreover, the report pointed to several available alternatives to chimpanzee use and called for increased support for the development of more alternative research methods. Prior to the IOM report, approximately 80%-90% of chimpanzees in laboratories were not being used and instead are warehoused in laboratories at a high cost to US taxpayers. Sanctuaries can provide higher standards of care at a lower cost to taxpayers.

Related Links:

Institute of Medicine




Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.